- Home
- FRPH vs AUTL Comparison
FRPH vs AUTL Comparison
Compare FRPH & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRPH | AUTL |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 368.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FRPH | AUTL |
|---|---|---|
| Price | $23.39 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 83.8K | ★ 3.8M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | $33,049,999.00 | ★ $51,128,000.00 |
| Revenue This Year | N/A | $658.11 |
| Revenue Next Year | N/A | $91.34 |
| P/E Ratio | $96.06 | ★ N/A |
| Revenue Growth | 5.21 | ★ 406.67 |
| 52 Week Low | $21.68 | $1.11 |
| 52 Week High | $32.27 | $2.88 |
Technical Indicators
Market Signals| Indicator | FRPH | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 50.18 | 59.11 |
| Support Level | $23.30 | $1.46 |
| Resistance Level | $23.75 | $1.66 |
| Average True Range (ATR) | 0.58 | 0.10 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 37.71 | 84.04 |
Price Performance
Historical ComparisonAbout FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.